OFICIAL Johnson & Johnson Newsroom

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

What happened
Based on Johnson & Johnson Newsroom · Jul 29, 2026

Johnson & Johnson finalized the $1 billion acquisition of Firefly Bio, Inc. to expand its oncology portfolio with the Firelink™ degrader antibody conjugate platform, targeting difficult-to-treat solid tumors including KRAS-driven cancers.

🚩 Report a correction ↗ Open source
Key points
·
With the close of the transaction, Johnson & Johnson further deepens its capabilities in next-generation antibody engineering and broadens its strategy for tackling complex tumor biology.
·
The Firelink™ DAC platform is designed to deliver highly selective protein degraders directly to cancer cells, enabling targeted activity while preserving healthy tissue—a key limitation of many current treatment approaches.
·
By bringing together Firefly Bio’s differentiated technology with its deep expertise in oncology and antibody engineering, the company is well positioned to accelerate the development of more precise and effective therapies.
·
Integrating Firefly Bio’s capabilities further strengthens this commitment, enabling new approaches to address some of the most challenging solid tumors, including those driven by KRAS.
Key numbers
·
for $1 billion in cash, securing the Firelink™ degrader antibody conjugate (DAC) platform.
·
The transaction, accounted for as an asset acquisition, will result in a $1 billion in-process research and development charge in Q3 2026.
·
Johnson & Johnson expects the deal to reduce adjusted operational earnings per share by $0.

Johnson & Johnson announced the completion of its acquisition of Firefly Bio, Inc. for $1 billion in cash, securing the Firelink™ degrader antibody conjugate (DAC) platform. The platform aims to deliver targeted protein degraders to cancer cells while minimizing damage to healthy tissue, addressing a key limitation in current oncology treatments. The acquisition strengthens Johnson & Johnson’s efforts to develop therapies for solid tumors, particularly those driven by KRAS mutations, where patient needs remain unmet.

The transaction, accounted for as an asset acquisition, will result in a $1 billion in-process research and development charge in Q3 2026. Johnson & Johnson expects the deal to reduce adjusted operational earnings per share by $0.46 in 2026 and $0.08 in 2027. The company has provided updated 2026 guidance in its SEC Form 8-K filing.

John Reed, M.D., Ph.D., Executive Vice President of Innovative Medicine, Research & Development at Johnson & Johnson, highlighted the strategic value of integrating Firefly Bio’s technology. He noted the combination of Firefly Bio’s platform with Johnson & Johnson’s oncology expertise could accelerate the development of more precise cancer therapies.

Johnson & Johnson emphasized its long-standing leadership in oncology and commitment to redefining cancer care standards. The acquisition of Firefly Bio further supports this goal by enabling new approaches to treat challenging solid tumors, including KRAS-driven cancers, through advanced antibody engineering.

Original source → Deals on Clipraptor.com →